MedInsights

What MedInsights does

MedInsights SAS is a Paris-based, privately-held AI-driven biotech company founded in 2022 that builds software and analytics tools for drug repositioning, de-risking, and clinical trial optimization, with a therapeutic focus on rare and metabo-inflammatory diseases. Its flagship platform, NEXUS-Rx, integrates proprietary explainable AI (xAI) models and deep graph learning across approximately 5 million drug-target combinations and over 25 heterogeneous data sources (clinical trials, omics datasets, patents, publications, and anonymized patient data) to surface novel drug-disease-target relationships. The platform is modular, comprising Genoptimizer (gene-disease network analysis), Pheno-Connect (gene-to-phenotype mapping), RxFinder (drug-target prioritization), Opti-Mouse (preclinical animal model analysis), and Clinicalyzer (clinical trial intelligence). Beyond NEXUS-Rx, the company has developed CardioTwin/MetaboTwin digital twins for cardiometabolic disease management using reinforcement learning, and a suite of GenAI and computer vision applications (ClinForecast, MorphoScope, MuseMouse).

MedInsights serves large and mid-size pharmaceutical companies, biotechnology firms focused on rare diseases, and academic and research institutions. Named commercial clients include Bayer and IPSEN, with academic and clinical partners spanning Karolinska University Hospital, Université Paris Cité (BFA), Institut Imagine, INEM, Institut Necker Enfants Malades, and Kyron bio. The company generates revenue through a mix of professional services for drug discovery engagements and subscription/recurring licensing of the NEXUS-Rx platform modules, using a quote-based "Book a demo" enterprise sales motion. It is also embedded in the European drug-repurposing ecosystem via membership in REPO4EU and the Paris Biotech Santé incubator. Senior leadership comprises Dr. Soham Saha (CEO) and Victor Hannothiaux (President), with scientific and strategic advisory support from Prof. Paolo Parini (Karolinska Institutet) and Dr. Kingsley Urakpo (NADDBio).

The company is registered as a société par actions simplifiée (SAS) under French law at 8 rue Milton, 75009 Paris, with an operational presence at the Paris Biotech Santé incubator (24 rue du faubourg Saint-Jacques, 75014 Paris). Headcount is reported at 1–10 employees, no institutional venture funding rounds are disclosed, and no revenue figure is publicly available; BPI France is referenced as a financial backer. Operating geographies are Western Europe and the Nordic region, with a flagship CardioTwin pilot underway in Sweden via Karolinska.

Name

MedInsights

Legal name

MedInsights SAS

Website

https://medinsights.fr

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

MedInsights SAS is a Paris-based AI-driven biotech that builds the NEXUS-Rx platform, using explainable AI and deep graph learning to identify drug-disease-target relationships and reposition therapies, primarily serving pharmaceutical companies and rare-disease research institutions.

Ownership category

akta.pro rank

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Drug Discovery Services: AI-driven drug repositioning and optimization services for pharmaceutical and biotech companies. Revenue generated through partnerships with drug developers seeking to identify novel drug-disease matches and accelerate drug development pipelines.
2. NEXUS-Rx Platform Licensing: Licensing of the NEXUS-Rx platform modules (Genoptimizer, Pheno-connect, RxFinder, Opti-Mouse, Clinicalyzer) to pharmaceutical companies for drug discovery and development support.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

MedInsights sells an AI-driven drug discovery software platform called NEXUS-Rx that uses proprietary explainable AI and deep graph learning to identify relationships between diseases, targets, and drugs across 25+ integrated data sources. The company packages this platform alongside additional Gen AI applications (ClinForecast, MorphoScope, MuseMouse) and a cardiometabolic digital twin product (CardioTwin/MetaboTwin), delivering these primarily to pharmaceutical, biotech, and academic research clients via direct enterprise sales.

Product overview

MedInsights offers a platform-plus-modules architecture centered on NEXUS-Rx, a comprehensive drug discovery framework. NEXUS-Rx comprises five integrated modules: Genoptimizer (gene expression and network analysis), Pheno-Connect (phenotypic connections), RxFinder (drug-target discovery), Opti-Mouse (animal model optimization), and Clinicalyzer (clinical trial intelligence). The company also provides CardioTwin/MetaboTwin for cardiometabolic digital twins, and Gen AI/xAI applications including ClinForecast (clinical trial optimization), MorphoScope (computer vision for behavioral analysis), and MuseMouse (preclinical model prediction).

Differentiator

Problem solved

Functional benefit

Brands

• NEXUS-Rx: A comprehensive AI-driven framework for drug repositioning, de-risking and optimization, encompassing clinical data analysis to drug mechanism exploration. Comprises modules including Genoptimizer, Pheno-connect, RxFinder, Opti-Mouse, and Clinicalyzer.
• Cardio Twin/MetaboTwin
• ClinForecast
• MorphoScope
• MuseMouse

Products and services

• NEXUS-Rx A fully-integrated AI-driven drug discovery framework for drug positioning, de-risking, and optimization, integrating proprietary explainable AI models with deep graph learning over 25+ data sources to identify relationships between disease-targets-drugs. Comprises modules for gene expression and network analysis (Genoptimizer), phenotypic connections (Pheno-Connect), drug-target prioritization (RxFinder), animal model optimization (Opti-Mouse), and clinical trial intelligence (Clinicalyzer). Sold to pharmaceutical, biotech, and academic research clients.
• CardioTwin/MetaboTwin Healthcare digital twin platform for cardiometabolic diseases that integrates diverse data (EHRs, labs, lifestyle, multi-omics, metabolites) into a unified interoperable system using explainable AI algorithms and the NEXUS-Rx framework. Includes a reinforcement-learning functional twin prototype that adapts recommendations to individual patient responses, with GDPR and FAIR-principles compliance.
• ClinForecast Gen AI assisted AI/ML application that uses public and private data from ClinicalTrials.gov and internal client resources to predict and optimize the efficiency and duration of clinical trials. Built for pharmaceutical sponsors and clinical operations teams seeking to shorten trial timelines.
• MorphoScope Computer vision application for automated tracking and annotation, segmentation, and ML-assisted explanation of behavior at scale from organelle to organism, supporting preclinical research and behavioral analysis workflows.
• MuseMouse Gen AI assisted application that uses publicly available open source data and genetic information of preclinical models to predict the best mimetic of disease conditions and progression, supporting preclinical model selection for drug discovery.

Quantifiable outcome

• Comprehensive network models for disease progression and drug interactions at molecular level
• +2 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability11 records

Feature11 records

Partnerships

Eight partnerships are on record, tiered core, flagship and major.

• Biologie Fonctionnelle et Adaptative (BFA) - Université Paris CitécoreStrategic or Co-development Partner · 8 August 2025Long-term partnership to leverage MedInsights' proprietary Nexus-Rx engine to accelerate discovery of new therapies for neurometabolic and compulsive/addictive disorders. The project uses AI and machine learning tools to identify potential drug compounds targeting a specific kinase enzyme linked to these conditions.
• REPO4EUcoreStrategic or Co-development PartnerMedInsights is a member of REPO4EU, a European research consortium focused on drug repurposing.
• Paris Biotech SantécoreStrategic or Co-development PartnerMedInsights is part of Paris Biotech Santé, a healthcare and biotech incubator/park in Paris providing networking and support for biotech companies.
• Karolinska University HospitalflagshipStrategic or Co-development PartnerPilot study underway for CardioTwin/MetaboTwin digital twin platform for cardiometabolic diseases in Swedish healthcare system. Leverages Karolinska's strong digital infrastructure and robust data governance.
• BayermajorTechnology or IntegrationPharmaceutical company client using MedInsights' drug positioning and discovery services for rare diseases.
• IPSENmajorTechnology or IntegrationPharmaceutical company client using MedInsights' drug positioning and discovery services.
• Prof. Paolo Parini (Scientific Advisor)coreOthersDirector of R&D, Education and Innovation at Karolinska Institutet and Karolinska University Hospital joined as Scientific Advisor to provide expertise in cardiometabolic diseases and AI-driven drug repositioning.
• Dr. Kingsley Urakpo (Strategic Advisor)coreOthersPharmaceutical Physician and Managing member of NADDBio LLC joined as Strategic Advisor to shape client partnerships and provide 360-degree biopharma ecosystem expertise.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning to identify novel therapeutics; directly comparable to MedInsights' NEXUS-Rx in target identification and repurposing use cases, though operating at significantly larger scale.
• Exscientia: AI-driven pharma company using automated drug design and active learning to accelerate small-molecule discovery; competes head-on with MedInsights in pharma-facing AI drug discovery and repositioning.
• Insitro: Machine learning-driven drug discovery platform integrating high-throughput biology with predictive models for target identification and patient stratification; comparable to NEXUS-Rx in computational biology approach.
• BenevolentAI: AI platform combining knowledge graphs and machine learning for drug discovery and repurposing; the closest analogue to MedInsights' graph learning + drug repositioning architecture.
• Owkin: France-based AI biotech using federated learning on patient data for drug discovery and clinical trial optimization; comparable to MedInsights on geography, AI-pharma focus, and French ecosystem membership.
• Iktos: Paris-based AI company specializing in generative AI for small molecule design and multi-parameter optimization; comparable French AI-drug discovery peer targeting pharma clients.
• Aqemia: Paris-based AI-driven drug discovery startup combining quantum physics and machine learning for hit identification; directly comparable as another French AI-pharma startup serving similar enterprise customers.
• Healx: AI-driven drug discovery company focused specifically on rare diseases, matching MedInsights' therapeutic focus; uses machine learning for drug repurposing and combination therapy identification.

Emerging players

• Biovista: AI drug repositioning platform identifying new indications for existing drugs; smaller scale but directly comparable in drug repurposing methodology and enterprise pharma positioning.
• Pharos AI: AI-driven drug repositioning and indication expansion platform; comparable in focus on drug repurposing for unmet medical needs using knowledge graph and ML approaches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/medinsights-fr/about

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MedInsights